Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05887492 · ClinicalTrials.gov registry record · Phase 1
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Tango Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 126
- Enrollment target
- 13
- Study locations
NCT05887492: Recruiting Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Tango Therapeutics.
NCT05887492 is a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer that is actively recruiting participants, run by Tango Therapeutics. The registered enrollment target is 126 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (81% lower). The trial reports 13 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05887492, a Phase 1 study of Non-Small Cell Lung Cancer and Lung Cancer, is actively recruiting participants, sponsored by Tango Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 126 participants
- Enrollment target
- 13
- Study locations
Study Summary
The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question\[s\] it aims to answer are: * the recommended dose for Phase 2 * to evaluate the safety and tolerability of the combination therapy * to determine the pharmacokinetics of TNG260 * to evaluate the initial antineoplastic activity Participants will receive study treatment until they experience an undesirable side effect, their disease progresses or until they withdraw consent.
Primary Outcome
To determine the MTD and RP2D(s) of TNG260 when administered in combination with pembrolizumab
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG TNG260
Study Locations (13)
Michigan
- Henry Ford Health System - Detroit
- START MidWest - Grand Rapids
New York
- NYU Langone Hematology Oncology Associates-Mineola - Mineola
- New York University Langone Health - New York
Texas
- US Oncology Investigational Products Center - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
Virginia
- NEXT Oncology Virginia - Fairfax
- US Oncology Investigational Products Center - Norfolk
California
- UCLA Hematology/Oncology - Santa Monica
Colorado
- SCRI at HealthOne - Denver
Florida
- Florida Cancer Specialists - Sarasota
Massachusetts
- Dana Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2023-06-12 |
| Est. Completion | 2026-06 |
| Phase | Phase 1 |
What NCT05887492 shows while recruiting
NCT05887492 is an interventional study that assigns participants to a tested intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (81% lower).
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05887492 lists 13 locations in 9 states (Michigan, New York, Texas).
Frequently Asked Questions
What is clinical trial NCT05887492 about?
NCT05887492 is a clinical study titled "Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors". The goal of this interventional clinical trial is to learn about TNG260, a CoREST inhibitor, in combination with pembrolizumab in patients with advanced solid tumors with a known STK11 mutation. The main question\[s\] it aims to answer are: * the recommended dose for Phase 2 * to evaluate the safe...
What is the current status of trial NCT05887492?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 126 participants. The study started on 2023-06-12. Estimated completion is 2026-06.
What conditions does trial NCT05887492 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer, Lung Adenocarcinoma, Solid Tumors, Adult.
What interventions are being tested in trial NCT05887492?
The interventions under investigation include: Pembrolizumab (DRUG), TNG260 (DRUG).
Who is sponsoring clinical trial NCT05887492?
This trial is sponsored by Tango Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05887492 being conducted?
This trial has 13 study locations across California, Colorado, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05887492's enrollment target sits among peer trials
126 215th of 454 higher than 240 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI